Two to retire from OXiGENE board as McMahon joins
This article was originally published in Scrip
OXiGENE, a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, has appointed Dr Gerald McMahon to its board of directors in anticipation of the impending retirement of William Shiebler and Mark Kessel. Mr Shiebler has served on the board for 10 years, and Mr Kessel since 2008. Dr McMahon joined MedImmune in 2010 and currently serves as senior vice-president of R&D.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.